Skip to main content
. Author manuscript; available in PMC: 2020 Dec 4.
Published in final edited form as: Neuron. 2019 Oct 21;104(5):869–884.e11. doi: 10.1016/j.neuron.2019.09.001

Figure 5. Reducing farnesyl-ykt6 enhances SNARE assembly and improves the lysosomal targeting of GCase.

Figure 5.

A) Ykt6 membrane shift analysis of SH-SY5Y cells expressing GFP-ykt6 wt or CS (n=3). B) Co-IP of GFP-ykt6 and bet1 in A53T iPSn (n=3). C) Ykt6 membrane shift analysis in FTI-treated SH-SY5Y wt a-syn cells or A53T iPSn (5nM farnesyltransferase inhibitors (FTI) LNK-754 (FTI-1) or LNK-3248 (FTI-2) for 5 days) (n=4). Sec22b was measured to assess specificity. D) SEC / western blot of FTI-1 treated SH-SY5Y cells. Quantification is shown below. E) Co-IP of GFP-ykt6 wt or mutant ykt6-SS, (cannot be palmitoylated or farnesylated) in FTI-treated SH-SY5Y cells (5nM LNK-754, 5d) (n=2). F) Immunofluorescence of GCase and LAMP2A in FTI-treated H4 a-syn cells transfected with scrambled (scrb) or ykt6 shRNA (n=3). Scale bar=10um. G) GCase maturation analysis in FTI-treated A53T iPSn by endo H (n=3). Values are the mean +/− SEM, *p<0.05. See also Figure S6.